Encouraged by our recent findings that rhIL-7-hyFc enhances CAR-T cell expansion, persistence and anti-tumor activity, a Phase 1b clinical trial is currently ongoing using rhIL-7-hyFc (efineptakin alfa, NeoImmuneTech, Inc.)following the standard of care CD19 CAR T-cell therapy in patients with Relapsed/Refractory Large B-cell Lymphoma (ClinicalTrials.gov ID: NCT05075603). Here, CD19 is linked to neoplasm.